Comparison of Vascular Responses Following New-Generation Biodegradable and Durable Polymer-Based Drug-Eluting Stent Implantation in an Atherosclerotic Rabbit Iliac Artery Model

被引:36
|
作者
Nakazawa, Gaku [1 ]
Torii, Sho [1 ]
Ijichi, Takeshi [1 ]
Nagamatsu, Hirofumi [1 ]
Ohno, Yohei [1 ]
Kurata, Fumi [1 ]
Yoshikawa, Ayako [1 ]
Nakano, Masataka [1 ]
Shinozaki, Norihiko [1 ]
Yoshimachi, Fuminobu [1 ]
Ikari, Yuji [1 ]
机构
[1] Tokai Univ, Sch Med, Dept Cardiol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan
来源
关键词
atherosclerosis; endothelialization; polymer; stent; BARE-METAL STENTS; MYOCARDIAL-INFARCTION; SPIRIT III; THROMBOSIS; RESTENOSIS; PATHOLOGY; TRIAL; PREDICTORS; MICRORNAS; HUMANS;
D O I
10.1161/JAHA.116.003803
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Incomplete endothelialization is the primary substrate of late stent thrombosis; however, recent reports have revealed that abnormal vascular responses are also responsible for the occurrence of late stent failure. The aim of the current study was to assess vascular response following deployment of biodegradable polymer-based Synergy (Boston Scientific) and Nobori (Terumo) drug-eluting stents and the durable polymer-based Resolute Integrity stent (Medtronic) in an atherosclerotic rabbit iliac artery model. Methods and Results-A total of 24 rabbits were fed an atherogenic diet, and then a balloon injury was used to induce atheroma formation. Synergy, Nobori, and Resolute Integrity stents were randomly implanted in iliac arteries. Animals were euthanized at 28 days for scanning electron microscopic evaluation and at 90 days for histological analysis. The percentage of uncovered strut area at 28 days was lowest with Synergy, followed by Resolute Integrity, and was significantly higher with Nobori stents (Synergy 1.1 +/- 2.2%, Resolute Integrity 2.0 +/- 3.9%, Nobori 4.6 +/- 3.0%; P< 0.001). At 90 days, inflammation score was lowest for Synergy (0.27 +/- 0.45), followed by Nobori (0.62 +/- 0.59), and was highest for Resolute Integrity (0.89 +/- 0.46, P< 0.001). Foamy macrophage infiltration within neointima (ie, neoatherosclerosis) was significantly less with Synergy (0.62 +/- 0.82) compared with Nobori (0.85 +/- 0.74) and Resolute Integrity (1.39 +/- 1.32; P=0.034). Conclusions-The biodegradable polymer-coated thin-strut Synergy drug-eluting stent showed the fastest stent strut neointimal coverage and the lowest incidence of neoatherosclerosis in the current animal model.
引用
收藏
页数:8
相关论文
共 50 条
  • [11] Coronary aneurysm formation following biodegradable polymer drug-eluting stent implantation
    Zhang, Feng
    Qian, Juying
    Dong, Lili
    Ge, Junbo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 160 (01) : E8 - E9
  • [12] Updated meta-analysis of biodegradable polymer drug-eluting stent versus second-generation durable polymer drug-eluting stent implantations
    Choe, J. C.
    Cha, K. S.
    Shin, J. Y.
    Ahn, J.
    Park, J. S.
    Lee, H. W.
    Oh, J. H.
    Choi, J. H.
    Lee, H. C.
    Hong, T. J.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1961 - 1961
  • [13] VASCULAR RESPONSE TO DRUG-ELUTING STENT IMPLANTATION IN A COMPLEX ATHEROSCLEROTIC PIG MODEL
    Patel, Dhavalkumar B.
    Llano, Raul
    Winsor-Hines, Dawn
    Seifert, Paul S.
    Hamamdzic, Damir
    Keane, Martin G.
    Huibregtse, Barbara A.
    Wilensky, Robert L.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E1660 - E1660
  • [14] Angioscopic Comparison of Arterial Repair 4 Months After the Implantation Between Bioresorbable Polymer Drug-Eluting Stent and Durable Polymer Drug-Eluting Stent
    Okuno, Shota
    Ishihara, Takayuki
    Fujita, Masashi
    Iida, Osamu
    Masuda, Masaharu
    Okamoto, Shin
    Nanto, Kiyonori
    Kanda, Takashi
    Tsujimura, Takuya
    Matsuda, Yasuhiro
    Ohashi, Takuya
    Tsuji, Aki
    Kawai, Hiroyuki
    Hata, Yosuke
    Mano, Toshiaki
    CIRCULATION, 2017, 136
  • [15] Ten-Year Clinical Outcomes of Biodegradable Versus Durable Polymer New-Generation Drug-Eluting Stent in Patients With Coronary Artery Disease With and Without Diabetes Mellitus
    Lenz, Tobias
    Koch, Tobias
    Joner, Michael
    Xhepa, Erion
    Wiebe, Jens
    Coughlan, J. J.
    Aytekin, Alp
    Ibrahim, Tareq
    Fusaro, Massimiliano
    Cassese, Salvatore
    Laugwitz, Karl-Ludwig
    Schunkert, Heribert
    Kastrati, Adnan
    Kufner, Sebastian
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (12):
  • [16] A Giant Coronary Artery Aneurysm Treated With a New-Generation Drug-Eluting Stent
    Engstrom, Krysthel
    Khan, Asaad A.
    LaRocca, Gina
    Kini, Annapoorna S.
    Sharma, Samin K.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2017, 10 (06) : C65 - C66
  • [17] Rotational Atherectomy and New-generation Drug-eluting Stent Implantation in De Novo Lesion
    Hachinohe, Daisuke
    Kashima, Yoshifumi
    Shitan, Hidemasa
    Watanabe, Tomohiko
    Sugie, Takuro
    Tadano, Yutaka
    Kaneko, Umihiko
    Kobayashi, Ken
    Kanno, Daitaro
    Enomoto, Morio
    Fujita, Tsutomu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (16) : S19 - S19
  • [18] Iimpact of metabolic syndrome on clinical outcome after new-generation drug-eluting stent implantation
    Lim, Y. -H.
    Shin, J.
    Kim, K. S.
    Kim, B. G.
    Lee, Y. G.
    Shin, J. H.
    Sung, K. C.
    EUROPEAN HEART JOURNAL, 2014, 35 : 977 - 977
  • [19] Comparison of early- and new-generation drug-eluting stent implantations for ostial right coronary artery lesions
    Watanabe, Yusuke
    Takagi, Kensuke
    Naganuma, Toru
    Nakamura, Sunao
    CARDIOVASCULAR THERAPEUTICS, 2017, 35 (02)
  • [20] Resolute® and xience V® polymer-based drug-eluting stents compared in an atherosclerotic rabbit double injury model
    Van Dyck, Christophe J.
    Hoymans, Vicky Y.
    Bult, Hidde
    Fransen, Erik
    Haine, Steven
    Bosmans, Johan M.
    Timmermans, Jean-Pierre
    Vrints, Christiaan J.
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2013, 81 (07) : E259 - E268